Compounded Tirzepatide Guide
Sources, Legality, Cost & Quality — 2025 Update
The FDA shortage exemption that made compounded tirzepatide widely available ended in March 2025. Here is everything you need to know: what changed, what it costs, how to evaluate quality, and what options remain.
The Shortage-to-Shortage-End Timeline
The FDA placed tirzepatide (Mounjaro/Zepbound) on the official drug shortage list due to explosive demand outpacing Eli Lilly's manufacturing capacity. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, this allowed licensed compounding pharmacies to legally produce tirzepatide for individual patients.
Lilly significantly expanded manufacturing and the FDA removed tirzepatide from the shortage list in late 2024. This triggered an immediate legal dispute — compounders argued the removal was premature given ongoing patient access issues; Lilly argued compounders were improperly competing with a now-available brand drug.
The FDA officially ended the shortage-based compounding exemption for tirzepatide and gave major 503B outsourcing facilities a 60-day wind-down period to cease commercial-scale compounded production. Individual 503A pharmacies retained limited ability to compound for specific patients with documented medical need, subject to state board rules.
Multiple compounding pharmacies and trade groups filed legal challenges to the FDA's shortage removal decision. Some courts issued temporary injunctions; the landscape remained fluid through 2025. Patients and providers should monitor FDA guidance and consult legal counsel before assuming compounding is permissible in their state.
Cost Comparison
| Option | Monthly Cost | Notes |
|---|---|---|
| Compounded Tirzepatide (503B) | $150–$350 | Legally restricted after March 2025 wind-down |
| Zepbound (brand, with coupon) | $550–$1,000 | Lilly Savings Card for commercially insured patients |
| Mounjaro (brand, with coupon) | $550–$1,000 | Lilly savings programs; diabetes indication |
| Zepbound (no insurance/coupon) | $1,200+ | List price varies by dose tier |
Evaluating Compounding Pharmacy Quality
503B Outsourcing Facilities
- • Registered with FDA — subject to federal cGMP standards
- • Regular FDA inspections (similar to pharmaceutical manufacturers)
- • Can produce larger batches for distribution
- • Higher regulatory bar = generally more reliable quality
- • Ask for FDA inspection history before purchasing
503A Compounding Pharmacies
- • Licensed by state pharmacy boards, not FDA directly
- • Must have valid patient-specific prescription
- • Quality varies widely by state and pharmacy
- • Cannot distribute commercially across state lines
- • Still legally able to compound for individual patients with documented need
What to Request
- • Certificate of Analysis (COA) for each batch
- • Sterility testing documentation
- • Endotoxin testing results
- • Active pharmaceutical ingredient (API) supplier information
- • Potency and purity assay method
Tirzepatide Base vs Salt
- • Brand Mounjaro uses tirzepatide HCl (hydrochloride salt form)
- • Many compounders used tirzepatide free base
- • Bioequivalence of base vs salt is debated — no peer-reviewed human PK data
- • Solubility and stability profiles may differ
- • Ask your pharmacy which form they use and why
Transitioning Back to Brand Medication
With the shortage exemption ended, many patients previously on compounded tirzepatide are transitioning back to brand Mounjaro or Zepbound. Here are the key considerations for a smooth transition:
- • Dose equivalence: Compounded doses may not directly map to brand dose tiers. Work with your prescriber to find the appropriate branded dose tier.
- • Lilly savings programs: Commercially insured patients can use the Lilly Savings Card. Uninsured patients may qualify for the Lilly Insulin Value Program or patient assistance programs.
- • Prior authorization: Many insurers require failed weight loss attempts or specific BMI/comorbidity documentation. Your doctor's office will typically assist with PA letters.
- • GoodRx / Mark Cuban Cost Plus Drugs: Check alternative pricing sources — Zepbound vials introduced in 2024 often carry lower list prices than auto-injector pens.
Frequently Asked Questions
Is compounded tirzepatide still legal in 2025?
The FDA officially ended the shortage exemption in March 2025 with a 60-day wind-down for commercial-scale 503B compounders. Individual 503A pharmacies retained limited ability to compound for specific patients with documented medical need. Legal challenges by compounders were ongoing through 2025 — always consult your physician and check current FDA guidance.
What is the difference between compounded tirzepatide and brand Mounjaro?
Brand Mounjaro uses tirzepatide hydrochloride salt. Many compounders used tirzepatide free base — raising bioequivalence questions. Quality also differs: 503B facilities face FDA cGMP oversight while 503A pharmacies are state-regulated. Reputable compounders provide COAs with sterility, potency, and endotoxin testing.
How much does compounded tirzepatide cost vs brand Zepbound?
Compounded tirzepatide during the shortage period cost $150-350/month. Brand Zepbound with Lilly Savings Card ranged from $550-1,000/month for commercially insured patients, and over $1,200 without any discount. The cost gap was the primary reason for compounded tirzepatide's popularity.
Track Every Dose — Brand or Compounded
Whether you are on brand Zepbound or navigating the compounded tirzepatide transition, Shotlee helps you log every injection, track weight changes, and document your protocol for your provider.
Start Tracking Free